# MTVA catalysts: MetaVia Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/mtva/catalysts

> MetaVia Inc. (MTVA) has 2 upcoming catalysts. The next is the DA-1726 topline data readout, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for MTVA?

MetaVia Inc. (MTVA) has 2 upcoming catalysts. The next is the DA-1726 topline data readout, Q1 2027. Press release filed with the SEC (EX-99): "All DA-1726 figures in this deck are from the Part 3B Day 109 interim dataset presented at the Precision Liver Symposium in November 2026; complete Part 3A and Part 3B topline data are expected in Q1 2027." [Calendar and source filings](https://sec-api.dev/companies/mtva/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001104659-26-126540, https://www.sec.gov/Archives/edgar/data/1638287/000110465926126540/mtva-ex99d2.htm (retrieved 2026-11-14). Last confirmed 2026-11-13. Cite: https://sec-api.dev/companies/mtva/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | MetaVia Inc. |
| Ticker | MTVA (Nasdaq) |
| SEC CIK | 1638287 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/mtva |

## Cash runway

Cash $8.8M as of 2026-09-30; quarterly burn $3.7M; about 7.1 months of runway at that rate (XBRL company facts, accession 0001104659-26-126541).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Sep 2024 | [DA-1726 topline data readout](https://sec-api.dev/pdufa/da-1726) | MTVA | obesity | completed, positive | "In September 2024, we announced positive top-line data from the" ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1638287/000155837025003386/mtva-20241231x10k.htm)) |
| Dec 2024 | [MetaVia Inc. topline data readout](https://sec-api.dev/companies/mtva/catalysts) | MTVA | presumed MASH | completed, positive | "o In December 2024, we announced positive topline 16-week results from the two-part Phase 2a clinical trial in patients with presumed MASH." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1638287/000110465926034911/mtva-20251231x10k.htm)) |
| December 18, 2024 | [Vanoglipel topline data readout](https://sec-api.dev/pdufa/vanoglipel) | MTVA | presumed MASH o Top-line data readout | completed, positive | "CAMBRIDGE, Mass., December 18, 2024 - MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced positive top-line 16-week results from the two-part Phase 2a clinical trial in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638287/000155837024016344/mtva-20241218xex99d1.htm)) |
| Q1 2025 | [Vanoglipel interim data readout](https://sec-api.dev/pdufa/vanoglipel) | MTVA |  | scheduled | "✓ Part 2 (MAD) interim data readout expected in Q1 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638287/000155837025000100/mtva-20250110xex99d1.htm)) |
| March 20, 2025 | [MetaVia Inc. earnings report](https://sec-api.dev/companies/mtva/catalysts) | MTVA |  | completed | "CAMBRIDGE, Mass., March 20, 2025 - MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the year ended December 31, 2024 and provided a corporate strategic update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638287/000155837025003344/mtva-20250320xex99d1.htm)) |
| Apr 2025 | [DA-1726 topline data readout](https://sec-api.dev/pdufa/da-1726) | MTVA | obesity further demonstrating its best-in-class potential | completed, positive | "April 2025: Reported additional positive top-line results from the 4-week MAD Part 2 of its Phase 1 clinical trial of DA-1726 for the treatment of obesity further demonstrating its best-in-class potential." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638287/000155837025010658/mtva-20250807xex99d1.htm)) |
| May 14, 2025 | [MetaVia Inc. earnings report](https://sec-api.dev/companies/mtva/catalysts) | MTVA |  | completed | "MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638287/000155837025007740/mtva-20250514xex99d1.htm)) |
| Jul 2025 | [DA-1726 trial start](https://sec-api.dev/pdufa/da-1726) | MTVA | obesity, to further explore the maximum tolerated dose | completed | "July 2025: Dosed the first patient in the 4-week 48 mg MAD cohort of the Phase 1 clinical trial of DA-1726, for the treatment of obesity, to further explore the maximum tolerated dose." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638287/000155837025010658/mtva-20250807xex99d1.htm)) |
| August 7, 2025 | [MetaVia Inc. earnings report](https://sec-api.dev/companies/mtva/catalysts) | MTVA |  | completed | "MetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638287/000155837025010658/mtva-20250807xex99d1.htm)) |
| Q4 2025 | [DA-1726 topline data readout](https://sec-api.dev/pdufa/da-1726) | MTVA |  | scheduled | "Top-Line Data Expected in the Fourth Quarter of 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638287/000155837025010415/mtva-20250806xex99d1.htm)) |
| November 6, 2025 | [MetaVia Inc. earnings report](https://sec-api.dev/companies/mtva/catalysts) | MTVA |  | completed | "MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638287/000110465925107447/mtva-20251106xex99d1.htm)) |
| January 5, 2026 | [DA-1726 topline data readout](https://sec-api.dev/pdufa/da-1726) | MTVA | Obesity | completed, positive | "On January 5, 2026, we announced positive topline data of Phase 1 MAD Part 2 non-titrated 48 mg Cohort 5 clinical trial of DA-1726." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1638287/000110465926004337/tm2528002-19_424b4.htm)) |
| March 26, 2026 | [MetaVia Inc. earnings report](https://sec-api.dev/companies/mtva/catalysts) | MTVA |  | completed | "MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638287/000110465926034907/mtva-20260326xex99d1.htm)) |
| April 10, 2026 | [DA-1726 trial start](https://sec-api.dev/pdufa/da-1726) | MTVA |  | completed | "On April 10, 2026, MetaVia Inc. (the "Company") issued a press release announcing that the first patient has been dosed in Part 3 of its Phase 1 clinical trial evaluating DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1638287/000110465926041784/mtva-20260410x8k.htm)) |
| May 14, 2026 | [MetaVia Inc. earnings report](https://sec-api.dev/companies/mtva/catalysts) | MTVA |  | completed | "MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638287/000110465926061148/mtva-20260514xex99d1.htm)) |
| August 6, 2026 | [MetaVia Inc. earnings report](https://sec-api.dev/companies/mtva/catalysts) | MTVA |  | completed | "MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638287/000110465926091981/mtva-20260806xex99d1.htm)) |
| Q4 2026 | [DA-1726 topline data readout](https://sec-api.dev/pdufa/da-1726) | MTVA |  | scheduled | "Sarah joins MetaVia at an important time as we prepare for the anticipated fourth quarter 2026 topline data readout from Part 3 of our Phase 1 clinical trial of DA-1726, evaluating higher target doses of 48 mg and 64 mg." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638287/000110465926115300/mtva-ex99d1.htm)) |
| Q4 2026 | [DA-1726 trial start](https://sec-api.dev/pdufa/da-1726) | MTVA |  | scheduled | "Having recently received Institutional Review Board (IRB) approval from the Clinical Pharmacology of Miami, we expect to initiate dosing in our Phase 1 Part 3, 16-week titration studies evaluating escalation to 48 mg in a single step and 64 mg using a two-step regimen in April, with data anticipated in the fourth quarter of 2026."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638287/000110465926034907/mtva-20260326xex99d1.htm)) |
| Q4 2026 | [MetaVia Inc. topline data readout](https://sec-api.dev/companies/mtva/catalysts) | MTVA |  | scheduled | "o Data readout for these Phase 1 studies is expected in the fourth quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638287/000110465926034907/mtva-20260326xex99d1.htm)) |
| November 5, 2026 | [DA-1726 interim data readout](https://sec-api.dev/pdufa/da-1726) | MTVA |  | completed, positive | "CAMBRIDGE, Mass., November 5, 2026 - MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming liver-related cardiometabolic diseases, today announced positive interim data from Part 3B of its Phase 1 clinical trial of DA-1726, a novel oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638287/000110465926123110/mtva-ex99d1.htm)) |
| November 13, 2026 | [MetaVia Inc. earnings report](https://sec-api.dev/companies/mtva/catalysts) | MTVA |  | completed | "MetaVia Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638287/000110465926126540/mtva-ex99d1.htm)) |
| Q1 2027 | [DA-1726 topline data readout](https://sec-api.dev/pdufa/da-1726) | MTVA |  | scheduled | "All DA-1726 figures in this deck are from the Part 3B Day 109 interim dataset presented at the Precision Liver Symposium in November 2026; complete Part 3A and Part 3B topline data are expected in Q1 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638287/000110465926126540/mtva-ex99d2.htm)) |
| 1H 2027 | [Vanoglipel trial start](https://sec-api.dev/pdufa/vanoglipel) | MTVA |  | scheduled | "o Initiation of a randomized, 12-week Phase 2a non-biopsy proof-of-concept study of vanoglipel in combination with resmetirom is targeted for the first half of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638287/000110465926126540/mtva-ex99d1.htm)) |

## Drugs

- [DA-1726](https://sec-api.dev/pdufa/da-1726): obesity, obesity further demonstrating its best-in-class potential, obesity, to further explore the maximum tolerated dose
- [Vanoglipel](https://sec-api.dev/pdufa/vanoglipel): presumed mash o top-line data readout, presumed mash, presumed metabolic dysfunction-associated steatohepatitis

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/mtva/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "MTVA catalysts: MetaVia Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/mtva/catalysts

```bibtex
@misc{secapidev_companies_mtva_catalysts_20261116,
  title        = {MTVA catalysts: MetaVia Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/mtva/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_mtva_catalysts_20261116","title":"MTVA catalysts: MetaVia Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/mtva/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
